Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy

Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3(mut+)) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3(mut+) AML ineligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Eunice S., Montesinos, Pau, Minden, Mark D., Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K., Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E., Gill, Stanley C., Rich, Elizabeth Shima, Tiu, Ramon V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653009/
https://www.ncbi.nlm.nih.gov/pubmed/35917453
http://dx.doi.org/10.1182/blood.2021014586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653009/
https://www.ncbi.nlm.nih.gov/pubmed/35917453
http://dx.doi.org/10.1182/blood.2021014586

Ejemplares similares